Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling

Ruijie Liu; Wenfang Wang; Wenfeng Li

doi:doi:10.18632/aging.205707

← Back

Research Paper Volume 16, Issue 19 pp 12769—12780

Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling

Figure 1. Bezafibrate improved cardiac function after coronary microembolization (CME) induction. (A) Left ventricular ejection fraction (LVEF); (B) Left ventricular fractional shortening (LVFS); (C) Cardiac output (CO); (D) Left ventricular end-diastolic diameter (LVEDd) (n=12, ^**, p<0.01 vs. control group; ^#, ^##, p<0.05, 0.01 vs. CME group).